<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6545">
  <stage>Registered</stage>
  <submitdate>21/11/2016</submitdate>
  <approvaldate>21/11/2016</approvaldate>
  <nctid>NCT02972840</nctid>
  <trial_identification>
    <studytitle>A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma</studytitle>
    <scientifictitle>A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ACE-LY-308</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lymphoma, Mantle Cell</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Acalabrutinib in combination with bendamustine and rituximab
Treatment: drugs - Placebo in combination with bendamustine and rituximab

Experimental: Acalabrutinib in combination with bendamustine and rituximab - Acalabrutinib administered twice per day (BID) orally (PO) plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.

Placebo Comparator: Placebo in combination with bendamustine and rituximab - Matching placebo administered BID PO plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.


Treatment: drugs: Acalabrutinib in combination with bendamustine and rituximab
Acalabrutinib in combination with BR

Treatment: drugs: Placebo in combination with bendamustine and rituximab
Placebo in combination with BR

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival per the Lugano Classification for NHL in Arm 1 compared to Arm 2</outcome>
      <timepoint>48 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Investigator-assessed progression-free survival per the Lugano Classification for NHL in Arm 1 compared to Arm 2</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Investigator-assessed overall response rate per the Lugano Classification for NHL in Arm 1 compared to Arm 2</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>IRC-assessed overall response rate per the Lugano Classification for NHL in Arm 1 compared to Arm 2</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival in Arm 1 compared to Arm 2</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>IRC-assessed duration of response per the Lugano Classification for NHL in Arm 1 compared to Arm 2</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>IRC assessed time to response per the Lugano Classification for NHL in Arm 1 compared to Arm 2</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Men and women, = 65 years of age.

          -  Pathologically confirmed MCL, with documentation of monoclonal CD20+ B cells that have
             a chromosome translocation t(11;14)(q13;q32) and/or overexpress cyclin D1.

          -  MCL requiring treatment and for which no prior systemic anticancer therapies have been
             received.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of = 2.

          -  Agreement to use highly effective forms of contraception during the study and 90 days
             after the last dose of acalabrutinib, 6 months after the last dose of bendamustine, or
             12 months after the last dose of rituximab, whichever is longest .</inclusivecriteria>
    <inclusiveminage>65</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias,
             congestive heart failure, or myocardial infarction within 6 months of first dose of
             study drug, or any Class 3 or 4 cardiac disease as defined by the New York Heart
             Association Functional Classification, or corrected QT interval (QTc) &gt; 480 msec
             (calculated using Friderica's formula: QT/RR0.33) at screening. Exception: Subjects
             with controlled, asymptomatic atrial fibrillation during screening are allowed to
             enroll on study.

          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function,
             resection of the stomach, extensive small bowel resection that is likely to affect
             absorption, symptomatic inflammatory bowel disease, partial or complete bowel
             obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.

          -  Uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as
             exhibiting ongoing signs/symptoms related to the infection and without improvement,
             despite appropriate antibiotics or other treatment), or intravenous anti infective
             treatment within 2 weeks before first dose of study drug.

          -  Concurrent participation in another therapeutic clinical trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>546</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2023</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <postcode> - Box Hill</postcode>
    <postcode> - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leper</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Kowloon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Tuen Mun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Peta? Tiqwa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Takapuna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Stravropol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Dnipro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kiev</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Acerta Pharma BV</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and
      rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle
      cell lymphoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02972840</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Shweta Gupta, BAMS, MD</name>
      <address>Acerta Pharma</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Rudy Narace</name>
      <address />
      <phone>1650-591-2800</phone>
      <fax />
      <email>ace-ly-308@acerta-pharma.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>